#United States #Scottsdale #Parkinson's Disease #CND Life Sciences #Syn-One

CND Life Sciences' Syn-One® Supports Parkinson's Disease Trial

CND Life Sciences, Inc., a forward-thinking medical technology enterprise based in Scottsdale, Arizona, has been making significant strides in the field of neurodiagnostic testing. Their innovative Syn-One® Biomarker Services were recently utilized in a pioneering Phase 2 clinical trial led by ABLi Therapeutics, with a focus on treating Parkinson's disease through the investigational drug, risvodetinib. This collaboration marks an essential advancement in understanding and quantifying the complexities of this debilitating neurodegenerative disorder.

The Syn-One Biomarker Services are designed to assist biopharmaceutical companies in enrolling patients more effectively in clinical trials and providing valuable insights during exploratory studies. In this context, they played a crucial role in measuring and visualizing the changes in levels of phosphorylated alpha-synuclein within cutaneous nerves of patients participating in the trial.

Understanding the Alpha-Synuclein Role

Alpha-synuclein is a protein that naturally resides in the brain and is heavily involved in synaptic function. However, in conditions like Parkinson's disease, abnormal accumulations of this protein lead to neurodegeneration. By targeting these deposits, researchers hope to halt or even reverse the progression of the disease. In ABLi's 201 Trial, results were presented at the 2025 Movement Disorders Society Annual Congress, indicating a quantifiable reduction in alpha-synuclein deposits among subjects treated with risvodetinib over a 12-week period.

Dr. Christopher Gibbons, CND’s Chief Scientific Officer, expressed optimism regarding these preliminary findings. He stated, "We are encouraged by the preliminary data generated using our Syn-One Biomarker Services in ABLi's 201 Trial for risvodetinib. While additional work needs to be done in future trials, these results support the potential role Syn-One can play in helping to quantify phosphorylated alpha-synuclein as a biomarker in clinical trials."

Pioneering Diagnostic Techniques

The services employed in the trial included the Syn-One Research Test and CND’s AI-assisted digital pathology tool, NerValence™, which utilizes advanced deep learning algorithms to enhance the analysis of neural structures. It delivers detailed, visual metrics that show the presence and distributions of abnormal alpha-synuclein levels detected inside nerves, which helps to reveal variations over time.

This advancement is especially noteworthy, being the first use of such a methodology in a clinical trial of a drug candidate aimed at treating Parkinson's disease. Dr. Milton Werner, Chairman and CEO of ABLi Therapeutics, highlights the significance of this approach, stating, "ABLi remains convinced that achieving disease modification can only be realized through the evaluation of intra-neuronal synuclein pathology, a fundamental aspect of progressive Parkinson's disease."

Future Directions and Contributions

In addition to the ABLi trials, CND Life Sciences continues to broaden the application of the Syn-One Biomarker Services. They have launched the 18-month Syn-Q Study, with support from the Michael J. Fox Foundation for Parkinson's Research, to further investigate the temporal dynamics of phosphorylated alpha-synuclein in patients diagnosed with the condition. This comprehensive approach aligns with CND's mission to enhance patient care amidst the looming diagnoses of neurodegenerative diseases.

CND operates under a CLIA-certified and CAP-accredited laboratory, and they have developed the Syn-One biomarker test to guide practitioners in diagnosing various synucleinopathies, including not just Parkinson's, but also dementia with Lewy bodies and multiple system atrophy. More than 3,000 healthcare professionals have harnessed the Syn-One results to refine diagnostic evaluations for their patients.

CND Life Sciences exemplifies cutting-edge innovation in the field of medical technology, merging advanced research methodologies with clinical application. As they continue their work, the importance of new insights into alpha-synuclein will undoubtedly play a pivotal role in shaping therapeutic strategies for Parkinson's disease and beyond.